Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Study of Peginterferon Alfa-2a in Combination With Ribavirin for the Treatment of CHC With Compensated LC

NCT00304551 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.

NCT NCT00304551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00304551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Study of Peginterferon Alfa-2a in Combination With Ribavirin for the Treatment of CHC With Compensated LC
Lead sponsor
Chugai Pharmaceutical
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2006
Completion date
June 30, 2010
Enrollment
180 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c, liver cirrhosis